Effect of Towne Live Virus Vaccine on Cytomegalovirus Disease after Renal Transplant

Abstract

Previous vaccination of seronegative renal transplant recipients with live cytomegalovirus results in reduction of disease severity mimicking the action of naturally derived immunity.

Management of cytomegalovirus infection after liver transplantation

“…Administration of a live attenuated vaccine prepared from the Towne and Toledo strains of CMV has been shown to reduce disease severity among high-risk (DϩR-) renal transplant recipients, although the incidence of infection and disease were not significantly reduced. 66 Theoretically, although complete protection against CMV may not be achieved by vaccination, partial immunity may suffice to prevent the development of serious manifestations of CMV infection and disease.…”

Processing of human cytomegalovirus glycoprotein B in recombinant adenovirus-infected cells

“…Although the protective efficacy of a live-attenuated HCMV vaccine has been demonstrated (Plotkin et al, 1991), theoretical concerns about latency and potential oncogenicity of live herpesvirus vaccines have prompted researchers to develop inert HCMV subunit vaccines or liverecombinant viruses expressing HCMV immunogens (Marshall & Plotkin, 1993).…”

A DNA-Based Vaccine for the Prevention of Human Cytomegalovirus-Associated Diseases

“…Although infection was not prevented, a subgroup of vaccinated patients did exhibit less severe disease manifestations. 37,43 A nonreplicating canarypox vector encoding HCMV gB has been investigated in Phase I studies alone and in combination with recombinant gB, 44,45 and a canarypox vaccine encoding pp65 has also been studied. 46 The latter induced CTL, lymphoproliferation, and antibody responses in all seronegative recipients in these Phase I trials.…”

“…Since that time, the Towne strain of HCMV has been attenuated by multiple in vitro passages and used in an investigational live virus vaccine in renal transplant recipients at high risk for post-transplant HCMV infection and disease. [35][36][37][38][39][40][41][42] Seronegative patients who received kidneys from seropositive donors were randomized to receive vaccine or placebo. Although infection was not prevented, a subgroup of vaccinated patients did exhibit less severe disease manifestations.…”